We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
+18.01%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$23.1B
AUM Growth
-$1.32B
Cap. Flow
-$3.13B
Cap. Flow %
-13.54%
Top 10 Hldgs %
44.45%
Holding
175
New
31
Increased
22
Reduced
37
Closed
21

Top Buys

Rank Stock Value
1
EA
Electronic Arts
EA
+$1.02B
2
EXAS
Exact Sciences
EXAS
+$514M
3
CYBR
CyberArk
CYBR
+$507M
4
SNPS icon
Synopsys
SNPS
+$444M
5
AVGO icon
Broadcom
AVGO
+$319M

Top Sells

Rank Stock Value
1
ADSK icon
Autodesk
ADSK
+$528M
2
TMO icon
Thermo Fisher Scientific
TMO
+$352M
3
TRU icon
TransUnion
TRU
+$333M
4
INTU icon
Intuit
INTU
+$333M
5
K
Kellanova
K
+$323M

Sector Composition

Rank Sector Weight
1 Healthcare 41.06%
2 Technology 12.67%
3 Financials 9.75%
4 Communication Services 8.88%
5 Consumer Discretionary 4.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
126
DELISTED
Soleno Therapeutics
SLNO
$232K ﹤0.01%
5,000
-148,000
-97% -$8.11M
PCVX icon
127
Vaxcyte
PCVX
$9.09B
$231K ﹤0.01%
+5,000
New +$224K
FOLD
128
DELISTED
Amicus Therapeutics
FOLD
$228K ﹤0.01%
16,000
– –
NEO icon
129
NeoGenomics
NEO
$2.23B
$223K ﹤0.01%
+19,000
New +$205K
ANNA
130
AleAnna Inc
ANNA
$113M
$223K ﹤0.01%
78,400
– –
ICLR icon
131
Icon
ICLR
$13B
$219K ﹤0.01%
1,200
– –
ESTA icon
132
Establishment Labs
ESTA
$2.16B
$219K ﹤0.01%
+3,000
New +$181K
OCUL icon
133
Ocular Therapeutix
OCUL
$2.37B
$219K ﹤0.01%
+18,000
New +$219K
SNDX icon
134
Syndax Pharmaceuticals
SNDX
$1.79B
$210K ﹤0.01%
10,000
– –
PGEN icon
135
Precigen
PGEN
$2.66B
$209K ﹤0.01%
+50,000
New +$193K
HR icon
136
Healthcare Realty
HR
$6.6B
$203K ﹤0.01%
12,000
– –
DYN icon
137
Dyne Therapeutics
DYN
$4.92B
$196K ﹤0.01%
10,000
– –
BCRX icon
138
BioCryst Pharmaceuticals
BCRX
$2.51B
$187K ﹤0.01%
24,000
– –
TVRD
139
Tvardi Therapeutics
TVRD
$23.7M
$186K ﹤0.01%
43,225
– –
ADPT icon
140
Adaptive Biotechnologies
ADPT
$4.18B
$179K ﹤0.01%
+11,000
New +$180K
ANNAW
141
AleAnna Inc Warrant
ANNAW
$5.28M
$163K ﹤0.01%
990,000
– –
ARDX icon
142
Ardelyx
ARDX
$989M
$134K ﹤0.01%
23,000
– –
BGLWW
143
Blue Gold Ltd Warrant
BGLWW
$366K
$132K ﹤0.01%
300,000
– –
RVMDW icon
144
Revolution Medicines Inc Warrant
RVMDW
$134M
$113K ﹤0.01%
120,085
– –
RANI icon
145
Rani Therapeutics
RANI
$97.1M
$105K ﹤0.01%
+78,000
New +$118K
ALT icon
146
Altimmune
ALT
$613M
$99.6K ﹤0.01%
27,600
– –
IOVA icon
147
Iovance Biotherapeutics
IOVA
$3.66B
$71K ﹤0.01%
26,000
– –
GERN icon
148
Geron
GERN
$983M
$56.8K ﹤0.01%
43,000
– –
EVH icon
149
Evolent Health
EVH
$556M
$56K ﹤0.01%
14,000
– –
CCCC icon
150
C4 Therapeutics
CCCC
$522M
$53.5K ﹤0.01%
28,000
– –
3 4 5
6
7

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Farallon Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Farallon Capital Management held 175 positions worth $23.1B, down 5.4% from $24.4B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Farallon Capital Management withdrew a net $3.13B in Q4 2025, closing 21 positions and reducing 37 holdings. Its most notable exit was Autodesk, an estimated $528M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 33% a quarter earlier, followed by Technology and Financials.

Against the trend, Farallon Capital Management opened a new position in Electronic Arts worth $1.03B.

  • Farallon Capital Management's largest Q4 2025 buy was Electronic Arts: 5,035,000 shares worth $1.03B.
  • Farallon Capital Management added most to Boston Scientific in Q4 2025, an estimated $264M increase.
  • Farallon Capital Management's biggest Q4 2025 reduction was Thermo Fisher Scientific, cutting an estimated $352M.
  • Farallon Capital Management fully exited Autodesk in Q4 2025, selling an estimated $528M.
  • Farallon Capital Management's ten largest holdings make up 44% of its $23.1B portfolio in Q4 2025.
  • Farallon Capital Management opened 31 new positions and closed 21 in Q4 2025.
  • Farallon Capital Management's portfolio value fell 5.4% quarter-over-quarter to $23.1B.

Based on Farallon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.